Differential response to 1α,25-dihydroxyvitamin D3 (1α,25(OH) 2D3) in non-small cell lung cancer cells with distinct oncogene mutations

Journal of Steroid Biochemistry and Molecular Biology

Volumn 136, Issue 1, 2013, Pages 264-270

  Zhang, Qiuhong ^a   Kanterewicz, Beatriz ^a   Shoemaker, Suzanne ^b   Hu, Qiang ^b   Liu, Song ^b   Atwood, Kristopher ^b   Hershberger, Pamela ^b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Epidermal growth factor receptor; K ras; Non small cell lung cancer; Vitamin D receptor

Indexed keywords

CALCITRIOL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; K RAS PROTEIN; MESSENGER RNA; VITAMIN D RECEPTOR;

CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CLONOGENIC ASSAY; COLONY FORMATION; CONTROLLED STUDY; DNA SEQUENCE; GENE ACTIVITY; GENE MUTATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; NUCLEOTIDE SEQUENCE; ONCOGENE; PROMOTER REGION; PROTEIN EXPRESSION; REPORTER GENE; REVIEW;

EID: 84881162561     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2012.09.022     Document Type: Review

References (35)

1. K. Nakagawa, A. Kawaura, S. Kato, E. Takeda, T. Okano, Metastatic growth of lung cancer cells is extremely reduced in vitamin D receptor knockout mice, Journal of Steroid Biochemistry and Molecular Biology 89-90 (1-5) (2004) 545-547.
2. R. Norton, M. O'Connell, Vitamin D potential in the prevention and treatment of lung cancer, Anticancer Research 32 (2012) 211-222.
3. R.M. Evans, The steroid and thyroid hormone receptor superfamily, Science 240 (1998) 889-895.
4. S. Swami, N. Raghavachari, U.R. Muller, Y.P. Bao, D. Feldman, Vitamin D growth inhibition of breast cancer cells: gene expression patterns assessed by cDNA microarray, Breast Cancer Research and Treatment 80 (2003) 49-62.
5. A.V. Krishnan, R. Shinghal, N. Raghavachari, J.D. Brooks, D.M. Peehl, D. Feldman, Analysis of Vitamin D-regulated genes in lncap human prostate cancer cells using cDNA microarrays, The Prostate 59 (2004) 243-251.
6. J.H. White, Profiling 1,25-dihydroxyvitamin D3-regulated gene expression by microarray analysis, Journal of Steroid Biochemistry and Molecular Biology 89-90 (2004) 239-244.
7. Q. Zhang, B. Kanterewicz, S. Buch, M. Petkovich, R. Parise, J. Beumer, Y. Lin, B. Diergaarde, P.A. Hershberger, CYP24 inhibition preserves 1α,25-dihydroxyvitamin D3 anti-proliferative signaling in lung cancer cells, Molecular and Cellular Endocrinology 355 (1) (2012) 153-161.
8. W. Zhou, R.S. Heist, G. Liu, K. Asomaning, D.S. Neuberg, B.W. Hollis, J.C. Wain, T.J. Lynch, E. Giovannucci, L. Su, et al., Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients, Journal of Clinical Oncology 25 (5) (2007) 479-485.
9. M. Srinivasan, A.V. Parwani, P.A. Hershberger, D.E. Lenzner, J.L. Weissfeld, Nuclear vitamin D receptor expression is associated with improved survival in non-small cell lung cancer, Journal of Steroid Biochemistry and Molecular Biology 123 (1-2) (2011) 30-36.
10. D.E. Prosser, G. Jones, Enzymes involved in the activation and inactivation of vitamin D, Trends in Biochemical Sciences 29 (12) (2004) 664-673.
11. D.G. Albertson, B. Yistra, R. Segraves, C. Collins, S.H. Dairkee, D. Kowbel, W.-L. Kuo, J.W. Gray, D. Pinkel, Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene, Nature Genetics 25 (2000) 144-146.
12. D.G. Beer, S.L. Kardia, C.C. Huang, T.J. Giordano, A.M. Levin, D.E. Misek, L. Lin, G. Chen, T.G. Gharib, D.G. Thomas, et al., Gene-expression profiles predict survival of patients with lung adenocarcinoma, Nature Medicine 8 (8) (2002) 816-824.
13. M.G. Anderson, M. Nakane, X. Ruan, P.E. Kroeger, J.R. Wu-Wong, Expression of VDR and CYP24A1 mRNA in human tumors, Cancer Chemotherapy and Pharmacology 57 (2006) 234-240.
14. R.A. Parise, M.J. Egorin, B. Kanterewicz, M. Taimi, M. Petkovich, A.M. Lew, S.S. Chuang, M. Nichols, T. El-Hefnawy, P.A. Hershberger, CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer, International Journal of Cancer 119 (8) (2006) 1819-1828.
15. G. Chen, S.H. Kim, A.N. King, L. Zhao, R.U. Simpson, P.J. Christensen, Z. Wang, D.G. Thomas, T.J. Giordano, L. Lin, et al., CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma, Clinical Cancer Research 17 (4) (2011) 817-826.
16. W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, B. Singh, R. Heelan, V. Rusch, L. Fulton, et al., EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib, Proceedings of the National Academy of Sciences of the United States of America 101 (36) (2004) 13306-13311.
17. Y. Wang, G. Schmid-Bindert, C. Zhou, Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians, Therapeutic Advances in Medical Oncology 4 (1) (2011) 19-29.
18. D.M. Jackman, V.A. Miller, L.A. Cioffredi, B.Y. Yeap, P.A. Janne, G.J. Riely, M.G. Ruiz, G. Giaccone, L.V. Sequist, B.E. Johnson, Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated nonsmall cell lung cancer patients: results of an online tumor registry of clinical trials, Clinical Cancer Research 15 (16) (2009) 5267-5273.
19. W. Pao, T.Y. Wang, G.J. Riely, V.A. Miller, Q. Pan, M. Ladanyi, M.F. Zakowski, R.T. Heelan, M.G. Kris, H.E. Varmus, KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib, PLoS Medicine 2 (1) (2005) e17.
20. C.E. Mitchell, S.A. Belinsky, J.F. Lechner, Detection and quantitation of mutant K-ras codon 12 restriction fragments by capillary electrophoresis, Analytical Biochemistry 224 (1) (1995) 148-153.
21. H. Okayama, T. Kohno, Y. Ishii, Y. Shimada, K. Shiraishi, R. Iwakawa, K. Furuta, K. Tsuta, T. Shibata, S. Yamamoto, et al., Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas, Cancer Research 72 (1) (2012) 100-111.
22. 3 24- hydroxylase gene promoter and identification of two vitamin D-responsive elements, Biochimica et Biophysica Acta 1263 (1995) 1-9.
23. Y. Ohyama, K. Ozono, M. Uchida, M. Yoshimura, T. Shinki, T. Suda, O. Yamamoto, Functional assessment of two vitamin D-responsive elements in the rat 25-hydroxyvitamin D3 24-hydroxylase gene, Journal of Biological Chemistry 271 (1996) 30381-30385.
24. 3 target genes, Molecular Endocrinology 19 (11) (2005) 2685-2695.
25. T. Mukohara, J.A. Engelman, N.H. Hanna, B.Y. Yeap, S. Kobayashi, N. Lindeman, B. Halmos, J. Pearlberg, Z. Tsuchihashi, L.C. Cantley, et al., Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations, Journal of the National Cancer Institute 97 (16) (2005) 1185-1194.
26. W. Pao, V.A. Miller, K.A. Politi, G.J. Riely, R. Somwar, M. Zakowski, M. Kris, H. Varmus, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain, PLoS Medicine 2 (3) (2005) e73.
27. M.G. Fakih, D.L. Trump, J.R. Muindi, J.D. Black, R.J. Bernardi, P.J. Creaven, J. Schwartz, M.G. Brattain, A. Hutson, R. French, et al., A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors, Clinical Cancer Research 13 (4) (2007) 1216-1223.
28. P.P. Dwivedi, G.E. Muscat, P.J. Bailey, J.L. Omdahl, B.K. May, Repression of basal transcription by vitamin D receptor: evidence for interaction of unliganded vitamin D receptor with two receptor interaction domains in RIP13delta1, Journal of Molecular Endocrinology 20 (3) (1998) 327-335.
29. F. Alimirah, A. Vaishnav, M. McCormick, I. Echchgadda, B. Chatterjee, R.G. Mehta, X. Peng, Functionality of unliganded VDR in breast cancer cells: repressive action on CYP24 basal transcription, Molecular and Cellular Biochemistry 342 (1-2) (2010) 143-150.
30. 3, Journal of Biological Chemistry 285 (20) (2010) 15599-15610.
31. 3-mediated induction, Journal of Biological Chemistry 275 (1) (2000) 47-55.
32. S.H. Kim, G. Chen, A.N. King, C.K. Jeon, P.J. Christensen, L. Zhao, R.U. Simpson, D.G. Thomas, T.J. Giordano, D.E. Brenner, et al., Characterization of vitamin D receptor (VDR) in lung adenocarcinoma, Lung Cancer 77 (2) (2012) 265-271.
33. I. Chung, A.R. Karpf, J.R. Muindi, J.M. Conroy, N.J. Nowak, C.S. Johnson, D.L. Trump, Epigenetic silencing of CYP24 in tumor-derived endothelial cells contributes to selective growth inhibition by calcitriol, Journal of Biological Chemistry 282 (12) (2007) 8704-8714.
34. R. Marik, M. Fackler, E. Gabrielson, M.A. Zeiger, S. Sukumar, V. Stearns, C.B. Umbricht, DNA methylation-related vitamin D receptor insensitivity in breast cancer, Cancer Biology and Therapy 10 (1) (2010) 44-53.
35. S. Toyooka, M. Tokumo, H. Shigematsu, K. Matsuo, H. Asano, K. Tomii, S. Ichihara, M. Suzuki, M. Aoe, H. Date, et al., Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers, Cancer Research 66 (3) (2006) 1371-1375.